Table 1.
Antiproliferative activity and TNF-α inhibition in LPS stimulated human PBMC of the compounds.
| Comp. no | IC50 (μM ± SD)a |
PBMC cell viability (%)b | ||
|---|---|---|---|---|
| NCI-H929 | U2932 | TNF-α | ||
| 3a | 32.24 ± 1.42 | >50 | >50 | 99 |
| 3b | 28.22 ± 0.92 | 36.38 ± 1.22 | 43.84 ± 1.88 | 98 |
| 3c | >50 | >50 | >50 | 100 |
| 9a | 9.26 ± 0.56 | 12.24 ± 0.58 | 5.48 ± 1.04 | 94 |
| 10a | 2.25 ± 0.09 | 5.86 ± 0.12 | 0.76 ± 0.08 | 99 |
| 10b | 16.28 ± 0.56 | 20.56 ± 0.82 | 21.28 ± 1.26 | 98 |
| 10c | 18.65 ± 0.83 | 26.32 ± 0.76 | 38.46 ± 1.38 | 100 |
| 10d | >50 | >50 | >50 | 99 |
| 12a | >50 | >50 | >50 | 100 |
| 12b | >50 | >50 | >50 | 100 |
| Lenalidomide | 1.12 ± 0.06 | 3.24 ± 0.11 | 0.13 ± 0.02 | 86 |
aIC50: the half maximal inhibitory concentration.
bCell viability measured by the CCK-8. The viable cell number was expressed as a percentage relative to control cells.